Lynx adverse-event record

Lynx Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 9 adverse event reports for Lynx, distributed across 0 distinct breeds currently tracked in the system. Of those reports, 1 involved a death outcome, producing a 11.1% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Lynx are Lethargy (see also Central nervous system depression in Neurological) (3 reports), Overdose (3 reports), Intentional misuse (2 reports), Application site hair coat discolouration (1 reports), with Lethargy (see also Central nervous system depression in Neurological) leading the reaction traffic at 3 submissions. On the product side, Selamectin is the single most-referenced drug with 2 reports, followed by Selamectin;Sarolaner (2), Oclacitinib Maleate (2), Velagliflozin Proline Monohydrate (2). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Lynx reporting patterns against other companion animals in the dataset.

Of the 9 Lynx reports with a coded outcome, Ongoing accounts for the largest share at 55.6%. Annual submission volume spans 1 to 3 reports across the 6 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 0 tracked lynx breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.